BackHarvard Apparatus Regenerative Technology Overview

Harvard Apparatus Regenerative Technology Current Cash

Latest current cash for HRGN: $1.9M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$1.85M
↑ 40.33% YoYΔ $532000.00 vs prior year quarter

Peer trimmed avg / median

Loading

Harvard Apparatus Regenerative Technology Current Cash History

Loading

Harvard Apparatus Regenerative Technology vs. peers: Current Cash Comparison

Loading

Harvard Apparatus Regenerative Technology Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Harvard Apparatus Regenerative Technology (HRGN) FAQ

Harvard Apparatus Regenerative Technology (HRGN) currently reports a current cash of $1.9M as of September 2026. That compares with $1.3M in the prior-year period — up 40.3% year over year. Use the charts on this page to explore Harvard Apparatus Regenerative Technology's current cash history and peer comparisons.

Harvard Apparatus Regenerative Technology's current cash increased from $1.3M to $1.9M — a 40.3% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Harvard Apparatus Regenerative Technology reported $1.9M in current cash as of September 2026. That compares with $1.3M in the prior-year period — up 40.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $1.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Harvard Apparatus Regenerative Technology, and consider following HRGN for alerts when major investors trade the stock.

Harvard Apparatus Regenerative Technology is classified in the Healthcare sector. On current cash, it currently shows $1.9M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HRGN with unrelated industries.